CompanyGraph
Sells a skin-worn glucose sensor whose 10-15 day design is locked to a specific FDA clearance competitors must replicate from scratch.
- Depends onDownstream position: depends on 8 industries, supplies 3
- ScaleMarket cap is higher than 95% of all stocks globally
- FinancialsAltman Z-Score: safe zone
- Interpretations12 currently firing — 3 · 9
What this company is and how it runs — written from structure, not news.
Dexcom sells a continuous glucose monitor in which an enzyme layer reacts with fluid just beneath the skin to send a blood-sugar reading to a smartphone every minute, and the sensor only keeps reading accurately if a biocompatible adhesive holds it in unbroken skin contact for the full ten to fifteen days. That adhesive and the enzyme chemistry were tested together in the clinical trials that earned the device its FDA Class III clearance, so the clearance covers the specific combination — meaning a competitor that swaps in a different adhesive or enzyme source has to run its own trials and wait twelve to eighteen months before it can access the same Medicare reimbursement codes or connect to insulin pumps like the Tandem t:slim, whose automated dosing software is certified against this particular cleared device. Because both the adhesive formulation and the enzyme chemistry require specialised biochemistry that cannot be handed off to outside manufacturers, the rate at which Dexcom can make sensors is capped by its own in-house production capacity, so demand can outrun supply even as the software that displays and stores the glucose data could serve millions more users at almost no added cost. If a supply disruption ever forced a reformulation of either component, the existing clearance would no longer cover the new combination, and the reimbursement codes and pump integrations that depend on it would break until a fresh clinical trial restored them.
How does this company make money?
The company sells sensors as consumables — each one lasts 10-15 days, so patients must keep buying replacements continuously. Payment flows primarily through insurance rather than directly from patients: Medicare covers the sensors under durable medical equipment and pharmacy benefit codes, and commercial insurers do the same. The 10-15 day use cycle means a steady, repeating revenue stream tied to the number of active users wearing sensors at any given time.
What makes this company hard to replace?
The FDA requires a separate 510(k) clearance submission for every competing CGM device, which takes 12-18 months and must be completed before a competitor's sensor can be prescribed or reimbursed. Insulin pump manufacturers like Tandem and Insulet certify their automated dosing software against specific devices, so switching sensors also means losing that pump integration until the new device goes through its own software certification. Insurance prior authorisation is tied to specific device codes, so a patient switching to a different CGM system must go through a new approval process with their insurer.
What limits this company?
The biocompatible adhesive must hold a waterproof seal against skin for up to 15 days without causing allergic reactions across very different skin types. Formulating to that standard requires specialised biochemistry expertise that cannot be handed off to outside manufacturers. Because that work stays in-house, how fast the company can produce and quality-check the adhesive sets the ceiling on how many sensors can ship.
What does this company depend on?
The company cannot operate without FDA 510(k) clearance for each sensor generation, a reliable supply of glucose oxidase enzyme for the biosensor to function, Bluetooth radio frequency spectrum for transmitting readings, Medicare and commercial insurance reimbursement codes that make the sensor affordable to patients, and lithium battery cells rated to run continuously for 10-15 days.
Who depends on this company?
Type 1 diabetics using automated insulin delivery systems like Tandem t:slim pumps rely on the device's continuous, certified glucose data to drive automated dosing — without it, those pumps cannot dose automatically. Endocrinologists managing insulin-dependent patients would lose the continuous glucose data streams they use to adjust therapy. Healthcare systems running remote patient monitoring programs would lose diabetes patient data feeds that are built into their electronic health records.
How does this company scale?
The smartphone app and cloud analytics that display and store glucose data can be extended to millions of additional users at almost no extra cost. What does not scale easily is the physical sensor: the glucose oxidase enzyme chemistry and the biocompatible adhesive formulation both require specialised biochemistry expertise that cannot be outsourced or automated, so manufacturing becomes a tighter bottleneck the faster the company tries to grow.
What external forces can significantly affect this company?
Medicare reimbursement rate changes for durable medical equipment directly affect how much the company earns per sensor and how many patients can afford one. If the FDA moves toward requiring more real-world evidence after a device is cleared, the cost of ongoing data collection rises. International supply chain disruptions for lithium battery components — the cells that power continuous 10-15 day operation — can delay sensor production.
Where is this company structurally vulnerable?
If the FDA issued new guidance treating the adhesive or the enzyme source as combination-product variables — meaning any change to either one requires a full new round of clinical trials — then any supply disruption that forced a reformulation would invalidate the existing clearance. That would cut off Medicare and insurance reimbursement and sever the certified data connections that insulin pumps like the Tandem t:slim depend on, all at once.
Price is read as structure — trend, levels, range, peak and volatility drawn on the chart. It does not predict where price goes next.
Sign in to view price data.
Sign in3 interpretations currently present — each is a set of fired observations whose alignment reads as one structural pattern. Click an observation to see the numbers behind it.
Screen for these patternsHow is this stock behaving?
Multi-Year Up-Close-Week Share With Profitability And Book-Value Growth
Three observations describe the present configuration: a high share of the trailing three years' weekly closes were higher than the prior week, the company has reported positive net income in each of the last five annual periods, and the book-value-increase-consistency composite over the trailing 5 years is elevated.
Near Multi-Tested High
Two structural conditions align: (1) a multi-year price band exists where the stock has, on at least two separated occasions, stopped advancing and pulled back, and (2) current price is back inside or just below that zone, near the top of its recent trading range. The retest is happening at a level the stock has reached before and turned away from.
Close In Upper Portion Of Recent Range, Bollinger Bands, And RSI
Current close sits in the upper portion of the 14-week high-low range; current close sits in the upper portion of its 20-week Bollinger Bands; RSI sits above its 20-week recent mean (Bollinger %B applied to RSI).
An interpretation is present only while every observation it reads stays fired (score ≥ 70). It describes what the aligned readings show — never a verdict, never a prediction.
The reported statements, read against the company's own industry.
9 interpretations currently present — each is a set of fired observations whose alignment reads as one structural pattern. Click an observation to see the numbers behind it.
Screen for these patternsIs this company financially stable?
MRQ Cash Elevated Relative To Total Debt With EBITDA And FCF Elevated Relative To Total Liabilities
Three observations have aligned: most-recent-quarter total cash is in the upper portion of its mapped range against most-recent-quarter total debt, EBITDA-to-total-liabilities is in the upper portion of its mapped range, and FCF-to-total-liabilities is in the upper portion of its mapped range.
How does this company use capital?
High OCF-to-NI With Multi-Year Gross-Profit Growth and Elevated-Margin-With-Deceleration
OCF is at or above net income for the most recent year; gross profit increased across the last 4 year-over-year transitions; EBIT margin is above the company's historical median while recent sales growth is below baseline (industry-benchmarked composite).
Three Asset-Base Ratios Elevated
Three asset-base observations have aligned: industry-benchmarked asset turnover is in the upper peer range, operating-income-to-total-assets is in the upper portion of its mapped range (scaled to 20%), and gross-profit-to-total-assets is in the upper portion of its mapped range (scaled to 50%).
Cumulative Treasury Stock Significant With Elevated ROE And FCF-To-Equity
Three observations have aligned: the cumulative treasury-stock balance is significant relative to current equity, return on equity sits in the upper industry-benchmarked peer range, and free cash flow as a share of equity book value is in the upper portion of its mapped range.
Cash Backing With OCF Coverage And Net Cash
Three observations co-occur: the weighted composite of net cash relative to market cap, OCF/revenue, operating margin, and ROE is in its elevated range; OCF/NI is in its elevated range; total cash at MRQ is at least equal to total debt. The configuration describes capital structure, cash-flow backing, and net-cash position at the current snapshot.
Cash Backing With Revenue And Income Streaks
Three observations co-occur: the weighted composite of net cash relative to market cap, OCF/revenue, operating margin, and ROE is in its elevated range; revenue increased every year for three years; net income was positive every year for three years. The configuration describes a present-state combination of capital structure, cash generation, profitability, and top-line growth.
Industry-Benchmarked Return on Capital Elevated
Three industry-benchmarked observations co-occur: return on equity is elevated, asset turnover is elevated, and return on assets is elevated. Because asset turnover and ROA both fire alongside ROE, the elevated ROE is not solely a leverage effect.
ROE, ROA, And Operating ROA Elevated
Three industry-benchmarked return-on-capital ratios are simultaneously in their elevated ranges: ROE, ROA, and operating ROA. Because ROA and operating ROA both fire alongside ROE, the configuration is not solely a function of equity multiplier; the underlying asset base is also producing elevated returns relative to peers.
Is this company growing?
Multi-Year Revenue, Profit, And Income Growth
Three multi-year observations co-occur: revenue increased year-over-year in each of the last three fiscal years, gross profit (absolute level) increased year-over-year in each of the last four fiscal years, and net income was positive in each of the last five fiscal years. The configuration describes growth-and-profitability persistence across three different windows.
An interpretation is present only while every observation it reads stays fired (score ≥ 70). It describes what the aligned readings show — never a verdict, never a prediction.
Shared structure with peers — never a ranking.
Structural observations derived from financial data, industry benchmarks, and supply chain position.
Financial Health
Supply Chain
Scale
Companies that share the same coordination system — how they create, deliver, or capture value.
Companies that share active interpretations — structural patterns currently present in both stocks.